Formulation and Packaging
1 tablet contains:
active ingredients: trimetazidine dihydrochloride 20 mg and macrogol;
inactive ingredients: microcrystalline cellulose, mannitol, magnesium stearate, titanium dioxide and dyes.
Application and Dosage
To be administered orally. Dosage is 40-60 mg per day divided into 2-3 intakes. The length of treatment course is to be prescribed by a doctor.
Pregnancy, lactation and hypersensitivity to the components of the drug.
Allergic response (including skin allergies), vertigo or headache.
No significant drug interactions were registered.
Storage Conditions and Shelf Life
Store at a temperature not higher than 25 °C (77 °F).
Keep out of the reach of children. Shelf life is 2 years.
Trimetazidine-Teva is an antihypoxic drug stimulating metabolism of the myocardium and sensorineural organs in case of ischemia.
Its active ingredient is trimetazidine which was the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Trimetazidine is usually prescribed as a long-term treatment of angina pectoris, and in some countries (including France) for tinnitus and dizziness. Controlled studies in angina patients have shown that trimetazidine increases coronary flow reserve, thereby delaying the onset of ischemia associated with exercise, limits rapid swings in blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates.
It improves left ventricular function in diabetic patients with coronary heart disease. Recently, it has been shown to be effective in patients with heart failure of different etiologies.
Trimetazidine inhibits beta-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. By preserving energy metabolism in cells exposed to hypoxia or ischaemia, trimetazidine prevents a decrease in intracellular ATP levels, thereby ensuring the proper functioning of ionic pumps and transmembrane sodium-potassium flow whilst maintaining cellular homeostasis.
Trimetazidine stimulates metabolism of cardiomyocytes and brain neuronal cells, thereby stabilizing oxygen consumption and myocardial contractility. In patients with angina pectoris, the drug has a pronounced effect of reducing blood pressure and regulating the heart rate after several weeks of administration.
Coronary heart disease with angina pectoris manifestations. The drug provides symptomatic treatment and prevents vascular vertigo, tinnitus, hearing impairment and chorioretinal vascular disorders. Trimetazidine-Teva can be administered both individually and in combination with other antianginals in case they do not provide the required effect.
- K McClellan, G Plosker (1999) Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions https://www.ncbi.nlm.nih.gov/pubmed/10439934
- R Belardinelli (2000) Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy https://www.ncbi.nlm.nih.gov/pubmed/11206102
- H Cross (2001) Trimetazidine for stable angina pectoris https://www.ncbi.nlm.nih.gov/pubmed/11336628
- Chrusciel et al (2014) Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease
- C Dézsi (2016) Trimetazidine in Practice: Review of the Clinical and Experimental Evidence https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856171/
- Ciapponi et al (2017) Trimetazidine for stable angina https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464521/
- von Bredow et al (2018) Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countries https://www.ncbi.nlm.nih.gov/pubmed/30379361/
- M Glezer (2018) The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study https://www.ncbi.nlm.nih.gov/pubmed/29766461